Optimized Background Regimen (OBR): Clinical Trials

3 trials of Optimized Background Regimen (OBR), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Active not recruiting 1, Completed 1, Terminated 1
Phase 21Active not recruiting 1

Follow Optimized Background Regimen (OBR): new trials by email Literature Review of Optimized Background Regimen (OBR) trials Research Report on Optimized Background Regimen (OBR)

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir - HIV-1-infection
Phase 2 / Phase 3Active not recruitingGilead Sciences722019-11-212026-10-01
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
ibalizumab, Optimized Background Regimen (OBR) - HIV
Phase 3CompletedTaiMed Biologics Inc.402015-08-012020-03-19
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
tipranavir, ritonavir, Optimized Background Regimen (OBR) - HIV Infections
Phase 3TerminatedBoehringer Ingelheim332007-02-012014-06-27

Conditions studied

HIV Infections (1)

Sponsors

Boehringer Ingelheim (1)  ·  Gilead Sciences (1)  ·  TaiMed Biologics Inc. (1)

Countries

United States (3)  ·  Canada (2)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Dominican Republic (1)  ·  France (1)  ·  Japan (1)  ·  Puerto Rico (1)  ·  South Africa (1)  ·  Thailand (1)

Results publications

PMID 30110589

NIH funding

2019 (1)